Glenmark

• 

  Cipla, Glenmark Recall Asthma Drugs Made In Indore From US Market

  Drug makers Cipla and Glenmark are recalling products from the American market due to manufacturing issues, according to the US health regulator.

• 

  Glenmark Pharma To Sell 75% Stake In Life Sciences To Nirma For $680 Million

  Drugmaker Glenmark Pharmaceuticals said on Thursday it would sell a 75% stake in unit Glenmark Life Sciences to detergent maker Nirma for 56.52 billion rupees ($679.84 million).

• 

  Glenmark Pharmaceuticals Recalls 1,200 Bottles Of "Subpotent" Hypertension Drug In US

  Glenmark Pharmaceuticals is recalling 1,200 bottles of a generic drug, used to treat high blood pressure, in the American market due to a manufacturing issue, according to the US Food and Drug Administration (USFDA).

• 

  Glenmark Pharmaceuticals Gets Final US Approval For Lacosamide Tablet

  Homegrown pharma major Glenmark Pharmaceuticals Ltd on Monday said it has received final approval from the US health regulator for its generic Lacosamide tablet, indicated for prevention and control of seizures.

• 

  5-Point Guide To The New Nasal Spray For Covid Cleared By India

  A nasal spray to treat adult COVID-19 patients has been launched in India after Mumbai-based developers Glenmark Pharmaceuticals received marketing clearances from the Drugs Controller General of India as part of an accelerated approval process.

• 

  First Nasal Spray For Treating Adult Covid Patients Launched In India

  Mumbai based innovation-driven global pharma company Glenmark has launched Nitric Oxide Nasal Spray (FabiSpray) in India, in partnership with SaNOtize, for treatment of adult patients suffering from COVID-19.

• 

  Stocks To Watch: ONGC, Glenmark Pharma, Apollo Hospitals, SpiceJet

  ONGC reported a decline in net profit to Rs 4,334.8 crore in the quarter ended June 2021 from Rs 6,734 crore in the same quarter last year

• 

  Glenmark Life Sciences Makes A Listless Debut; Lists At 4% Premium

  The shares of Glenmark Life Sciences opened at Rs 751 on the BSE, a premium of 4 per cent compared to the issue price of Rs 720.

• 

  Glenmark Life Sciences To Debut Tomorrow. Here's What To Expect

  Glenmark Life Sciences IPO comprised a fresh issue of Rs 1,060 crore and an offer-for-sale of Rs 453.60 crore by the promoters

• 

  Glenmark Life Sciences IPO: How To Check The Allotment Status?

  Glenmark Life Sciences IPO consisted of a fresh issue of Rs 1,060 crore and an offer for sale of Rs 453.60 crore by the promoters

• 

  Glenmark Life Sciences IPO Subscribed Nearly 45 Times On Final Day Of Issue

  Glenmark Life Sciences' share sale via initial public offering (IPO) was subscribed by 44.17 times on Thursday, July 29- the third and final day of its issue.

• 

  Glenmark Life Sciences IPO Subscribed Nearly 6 Times On Second Day Of Issue

  Glenmark Life Sciences' share sale via initial public offering (IPO) was oversubscribed by 5.78 times on Wednesday, July 28 - the second day of its issue.

• 

  Glenmark Life Sciences IPO Fully Subscribed Within Hours Of Opening

  Glenmark Life Sciences' Rs 1,513 crore IPO comprises of fresh issue of Rs 1,060 crore and an offer for sale of Rs 453.60.

• 

  Glenmark Life Sciences IPO Opens Today

  Glenmark Life Sciences IPO, which will be open for three days until July 29, will consist of a fresh issue of Rs 1,060 crore and an offer for sale of up to 6.30 million shares

• 

  Glenmark Life Sciences IPO To Open Tomorrow. Should You Subscribe?

  Glenmark Life Sciences' IPO will consist of a fresh issue of Rs 1,060 crore and an offer for sale of up to 6.30 million shares by Glenmark Pharmaceuticals